p53-Regulated hexokinase 1b is a novel target for metabolic theraphy against non-small-cell lung cancer

Warning The system is temporarily closed to updates for reporting purpose.

Yozgat, Yasemin (2019) p53-Regulated hexokinase 1b is a novel target for metabolic theraphy against non-small-cell lung cancer. [Thesis]

[img]PDF - Repository staff only until 21 January 2022 - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Official URL: https://risc01.sabanciuniv.edu/record=b2352779 _ (Table of contents)


Deregulation of glycolysis is common in non-small cell lung cancer (NSCLC). p53 controls the cellular metabolism pathway by activating hexokinases (HKs) to increase glycolysis. HK enzymes catalyze the phosphoryl-group-transfer in glucose metabolism. Unlike HK2, HK1 has several transcript variants. However, the functional differential roles of HK1 isoforms in glucose metabolism and the malignant tumor progression are still elusive. Here, we show that primary NSCLC patient tumor cells metabolically differ from the normal lung epithelium in that they display predominant expression of one of the HK1 isoforms, hexokinase1b (HK1b). Interestingly, we show that p53 positively regulates HK1b expression using CRISPR-Cas9 system. We utilized CRISPR-Cas9 system to selectively target specific HK1b isoform in NSCLC and show that silencing HK1b in NSCLC cells inhibits tumorigenesis through diminishing glycolysis and proliferation. Finally, HK1b deletion sensitizes NCLC cells to cisplatin treatment and the combination therapy synergistically increases both the p53- mediated apoptotic cell death by cisplatin and autophagic cell death by increased formation of LC3-II associated autophagic vesicles and myelinoid bodies in an AMPK-independent manner. Our findings reveal that targeting HK1b isoform alone or in combination with cisplatin may represent a novel strategy for NSCLC patients

Item Type:Thesis
Uncontrolled Keywords:Non-small cell lung cancer (NSCLC). -- Hexokinase 1b. -- Tumor suppressor 53 (p53). -- Glycolysis. -- Cisplatin. -- Drug targets. -- Apoptosis. -- Autophagy. -- Küçük hücreli dışı akciğer kanseri (KHDAK). -- Heksokinaz 1b. -- p53. -- glikoliz. -- Cisplatin. -- İlaç hedefleri apoptoz. -- Otofaji.
Subjects:T Technology > TA Engineering (General). Civil engineering (General) > TA164 Bioengineering
ID Code:39750
Deposited By:IC-Cataloging
Deposited On:10 Mar 2020 14:01
Last Modified:27 Jul 2021 13:55

Repository Staff Only: item control page